***In vivo* imaging of cannabinoid type 2 receptors, functional and structural alterations in mouse model of cerebral ischemia by PET and MRI**

Ruiqing Ni,^{1,2} Adrienne Müller Herde,³ Ahmed Haider,³ Claudia Keller,³ Georgios Louloudis,¹ Markus Vaas,¹ Roger Schibli,³ Simon M. Ametamey,³ Jan Klohs,¹ Linjing Mu^{3,4*}

¹Institute for Biomedical Engineering, University of Zurich & ETH Zurich, Zurich, Switzerland

²Institute for Regenerative Medicine, University of Zurich, Zurich, Switzerland

³Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland

⁴Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland

Corresponding author: Dr. Linjing Mu

Author's details

Dr. Linjing Mu

Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland

Address: ETH Zürich, HCI E 388.1 Vladimir-Prelog-Weg 1-5/10 Zürich 8093

Email: linjing.mu@pharma.ethz.ch

Phone: +41 44 633 61 96

Abstract

Background and purpose: Brain ischemia is one of the most important pathologies of the central nervous system. Non-invasive molecular imaging methods have the potential to provide critical insights into the temporal dynamics and follow alterations of receptor expression and metabolism in ischemic stroke. The aim of this study was to assess the cannabinoid type 2 receptors (CB₂R) levels in transient middle cerebral artery occlusion (tMCAO) mouse models at subacute stage using positron emission tomography (PET) with our novel tracer [¹⁸F]RoSMA-18-d6, and structural imaging by magnetic resonance imaging (MRI).

Methods: Our recently developed CB₂R PET tracer [¹⁸F]RoSMA-18-d6 was used for imaging the neuroinflammation at 24 h after reperfusion in tMCAO mice. The RNA expression levels of CB₂R and other inflammatory markers were analyzed by quantitative real-time polymerase chain reaction using brain tissues from tMCAO (1 h occlusion) and sham-operated mice. [¹⁸F]fluorodeoxyglucose (FDG) was included for evaluation of the cerebral metabolic rate of glucose (CMR_{glc}). In addition, diffusion-weighted imaging and T₂-weighted imaging were performed for anatomical reference and delineating the lesion in tMCAO mice.

Results: mRNA expressions of inflammatory markers *TNF-α*, *Iba1*, *MMP9* and *GFAP*, *CNR2* were increased at 24 h after reperfusion in the ipsilateral compared to contralateral hemisphere of tMCAO mice, while mRNA expression of the neuronal marker *MAP-2* was markedly reduced. Reduced [¹⁸F]FDG uptake was observed in the ischemic striatum of tMCAO mouse brain at 24 h after reperfusion. Although higher activity of [¹⁸F]RoSMA-18-d6 in *ex-vivo* biodistribution studies and higher standard uptake value ratio (SUV_R) were detected in the ischemic ipsilateral

compared to contralateral striatum in tMCAO mice, the *in-vivo* specificity of [¹⁸F]RoSMA-18-d6 was confirmed only in the CB₂R-rich spleen.

Conclusions: This study revealed an increased [¹⁸F]RoSMA-18-d6 measure of CB₂R and a reduced [¹⁸F]FDG measure of CMRglc in ischemic striatum of tMCAO mice at subacute stage. [¹⁸F]RoSMA-18-d6 might be a promising PET tracer for detecting CB₂R alterations in animal models of neuroinflammation without neuronal loss.

Key words: cannabinoid type 2 receptor; [¹⁸F]RoSMA-18-d6; ischemic stroke; neuroinflammation; magnetic resonance imaging; positron emission tomography

Introduction

The pathophysiology of ischemic stroke is complex and associated with a myriad of cellular and molecular pathways. The severe reduction in cerebral blood flow (CBF) initiates a cascade of hemodynamic, vascular and inflammatory processes in a time-dependent manner in the supplied brain territory, and subsequent defensive response for repair related to lesion expansion and containment. Irreversible tissue damage occurs in the core of the ischemic area; while neurons in the ischemic penumbra face excitotoxicity, peri-infarct polarizations, inflammation and apoptosis, leading to a secondary tissue damage and expansion of the lesion if reperfusion cannot be restored within an early time frame [2-4]. Neuroinflammation post stroke has been an important therapeutic target. Anti-inflammatory, immunomodulatory treatments and microglia-targeted therapy were evaluated in clinical stroke trials [5-7]. Thus, there is a need for imaging the regional neuroinflammatory pattern for understanding disease mechanism and for therapeutic monitoring.

Positron emission tomography (PET) using [^{18}F]fluorodeoxyglucose ([^{18}F]FDG) for cerebral metabolic rate of glucose (CMR_{glc}), [^{15}O]H₂O for perfusion imaging, and diffusion weighted (DW) magnetic resonance imaging (MRI) are valuable tools to support understanding of the pathophysiology in patients with ischemic stroke [3, 8-14]. However, *in vivo* imaging of neuroinflammation and gliosis is challenging [12, 13, 15]. One reason is that the astrocytes and microglia are highly dynamic and heterogeneous in their subtypes, locations and activation status. Additionally, the identification of an ideal target for neuroinflammation imaging is highly demanding. Translocator protein (TSPO) is the most widely used neuroinflammation target for PET imaging. [^{11}C]PK-11195, the first generation TSPO PET tracer, and several second-generation tracers such as [^{11}C]DAA1106, [^{11}C]PBR06, [^{11}C]PBR28, [^{11}C]GE180, and

[¹⁸F]DPA-713, [¹⁸F]DPA-714 [16-24] have been evaluated in (pre)-clinical studies. So far, imaging neuroinflammation with TSPO PET tracers yielded controversial results in rodents and patients with ischemic stroke [1, 13, 20]. Thus, the development of novel PET probes for visualizing alternative targets in neuroinflammation have received great attention in recent years [25-27].

Cannabinoid type 2 receptors (CB₂R) are mainly expressed by immune cells including monocytes and macrophages. In the brain, CB₂Rs are primarily found on microglia and have low expression levels under physiological conditions [2, 4, 28]. Upregulation of brain CB₂R expression is reported under acute inflammation such as ischemic stroke, and related to lesion extension in the penumbra and subsequent functional recovery [29]. Treatment with CB₂R agonists has been shown to be neuroprotective and attenuates macrophage/microglial activation in the mouse models of cerebral ischemia [29, 42-45]. CB₂R is also upregulated in other brain diseases with involvement of inflammation/microglia under chronic inflammation in neurodegenerative diseases such as Alzheimer's disease [30-33] and senescence-accelerated models [34], associated with amyloid-β deposits [28, 35-41].

Several structural scaffolds of CB₂R PET tracers have recently been developed [46-50] including pyridine derivatives, oxoquinoline derivatives; thiazole derivatives [51, 52]; oxadiazole derivatives [53]; carbazole derivatives [54]; imidazole derivative [55]; and thiophene derivatives [56, 57]. In this study, our newly developed pyridine derivative [¹⁸F]RoSMA-18-d6, which exhibited sub-nanomolar affinity and high selectivity towards CB₂R (K_i: 0.8 nM, CB₂R/CB₁R > 12'000) [58] is selected as the CB₂R PET tracer.

The aim of the current study was to evaluate the novel CB₂R tracer [¹⁸F]RoSMA-18-d6 in the transient middle cerebral artery occlusion (tMCAO) mouse models of focal cerebral ischemia

[60-66] using microPET. In addition, [^{18}F]FDG was included for evaluation of the cerebral metabolic rate of glucose (CMR_{glc}). Diffusion-weighted imaging and T₂-weighted imaging were performed for anatomical reference and for delineating the lesion in tMCAO mice.

Methods

Radiosynthesis

[^{18}F]RoSMA-18-d6 was synthesized by nucleophilic substitution of the tosylate precursor with [^{18}F]KF/Kryptofix222 in acetonitrile [58]. The crude product was purified by reverse phase semi-preparative high-performance liquid chromatography and formulated with 5 % ethanol in water for intravenous injection and for biological evaluations. In a typical experiment, a moderate radiochemical yield of ~ 12 % (decay corrected) was achieved with a radiochemical purity > 99 %. The molar activities ranged from 156 to 194 GBq/ μmol at the end of synthesis. The identity of the final product was confirmed by comparison with the HPLC retention time of the non-radioactive reference compound by co-injection. [^{18}F]FDG was obtained from a routine clinical production from the University Hospital Zurich, Switzerland.

Animals

Twenty-four male C57BL/6J mice were obtained from Janvier Labs (Le Genest-Saint-Isle, France). The mice were scanned at 8–10 weeks of age (20–25 g body weight). Mice were randomly allocated to sham-operation (n = 10) or tMCAO (n = 14). Mice underwent MRI, μPET / computed tomography (CT), and 2,3,5-Triphenyltetrazolium chloride (TTC) histology staining for validation 24 h or 48 h after reperfusion. Animals were housed in ventilated cages inside a temperature-controlled room, under a 12-hour dark/light cycle. Pelleted food

(3437PXL15, CARGILL) and water were provided *ad-libitum*. Paper tissue and red Tecniplast mouse house® (Tecniplast, Milan, Italy) shelters were placed in cages as environmental enrichments. All experiments were performed in accordance with the Swiss Federal Act on Animal Protection and were approved by the Cantonal Veterinary Office Zurich (permit number: ZH018/14 and ZH264/16).

Surgeries for tMCAO and sham-operation were performed using standard-operating procedures as described before [67, 68]. Anaesthesia was initiated by using 3 % isoflurane (Abbott, Cham, Switzerland) in a 1:4 oxygen/air mixture, and maintained at 2 %. Before the surgical procedure, a local analgesic (Lidocaine, 0.5 %, 7 mg/kg, Sintetica S.A., Switzerland) was administered subcutaneously (s.c.). Temperature was kept constant at 36.5 ± 0.5 °C with a feedback controlled warming pad system. All surgical procedures were performed in 15-30 min. After surgery, buprenorphine was administered as s.c. injection (Temgesic, 0.1 mg/kg b.w.), and at 4 h after reperfusion and supplied thereafter via drinking water (1 mL/32 mL of drinking water) until 24 h or 48 h. Animals received softened chow in a weighing boat on the cage floor to encourage eating. tMCAO animals were excluded from the study if they met one of the following criteria: Bederson testing was performed 2h post-reperfusion. Bederson score of 0, no reflow after filament removal, and premature death.

mRNA isolation, reverse-transcription reaction and real-time polymerase chain reaction

Brain hemispheres of C57BL/6 mouse, tMCAO mice at 24 h and 48 h post reperfusion were used for total mRNA isolation according to the protocols of the Isol-RNA Lysis Reagent (5 PRIME, Gaithersburg, USA) and the bead-milling TissueLyser system (Qiagen, Hilden,

Germany). QuantiTect® Reverse Transcription Kit (Qiagen, Hilden, Germany) was used to generate cDNA. The primers (Microsynth, Balgach, Switzerland) used for the quantitative polymerase chain reaction (qPCR) are summarized in **Supplementary Table 1**. Quantitation of *CNR2*, *Iba1*, *TNF-α*, *MMP9*, *GFAP* and *MAP-2* mRNA expression was performed with the DyNAmo™ Flash SYBR® Green qPCR Kit (Thermo Scientific, Runcorn, UK) using a 7900 HT Fast Real-Time PCR System (Applied Biosystems, Carlsbad, USA). The amplification signals were detected in real-time, which permitted accurate quantification of the amounts of the initial RNA template during 40 cycles according to the manufacturer's protocol. All reactions were performed in duplicates and in two independent runs. Quantitative analysis was performed using the SDS Software (v2.4) and a previously described 2^{-ΔΔCt} quantification method [69]. The specificity of the PCR products of each run was determined and verified with the SDS dissociation curve analysis feature.

In vivo MRI

Data were acquired at 24 h after reperfusion on a 7 T Bruker Pharmascan (Bruker BioSpin GmbH, Germany), equipped with a volume resonator operating in quadrature mode for excitation and a four element phased-array surface coil for signal reception and operated by Paravision 6.0 (Bruker BioSpin) [67, 70-72]. Mice were anesthetized with an initial dose of 4 % isoflurane in oxygen/air (200:800 ml/min) and maintained at 1.5 % isoflurane in oxygen/air (100:400 ml/min). Body temperature was monitored with a rectal temperature probe (MLT415, ADInstruments) and kept at 36.5 °C ± 0.5 °C using a warm water circuit integrated into the animal support (Bruker BioSpin GmbH, Germany). T₂-weighted MR images were obtained using a spin echo sequence (TurboRARE) with an echo time 3 ms, repetition time 6 ms, 100

averages, slice thickness 1 mm, field-of-view $2.56 \text{ cm} \times 1.28 \text{ cm}$, matrix size 256×128 , giving an in-plane resolution of $100 \mu\text{m} \times 100 \mu\text{m}$. For DWI, a four-shot spin echo–echo planar imaging sequence with an echo time = 28 ms, repetition time = 3000 [70, 71] acquired with a field-of-view of $3.3 \text{ cm} \times 2 \text{ cm}$ and a matrix size of 128×128 , resulting in a nominal voxel size of $258 \mu\text{m} \times 156 \mu\text{m}$. Diffusion-encoding was applied in the x-, y-, and z-directions with b-values of 100, 200, 400, 600, 800, and 1000 s/mm^2 , respectively, acquisition time 3 min 48 s. The ischemic lesion was determined as an area of significant reduction of the apparent diffusion coefficient (ADC) value compared with the unaffected contralateral side [73]. On T_2 -weighted images, the lesion was determined as an area of hyperintensities compared with the contralateral side.

In vivo microPET studies

MicroPET/CT scans were performed at 24 h after reperfusion with a calibrated SuperArgus μ PET/CT scanner (Sedecal, Madrid, Spain) with an axial field-of-view of 4.8 cm and a spatial resolution of 1.6–1.7 mm (full width at half maximum). tMCAO and the sham-operated C57BL/6J mice were anesthetized with ca. 2.5 % isoflurane in oxygen/air (1:1) during tracer injection and the whole scan time period. The formulated radioligand solution ($[^{18}\text{F}]\text{FDG}$: 9.9–11 MBq or $[^{18}\text{F}]\text{RoSMA-18-d6}$: 7.2–13 MBq) was administered via tail vein injection, and mice were dynamically scanned for 60 min. For blocking experiments, 1.5 mg/kg GW405833 was dissolved in a vehicle of 2 % Cremophor (v/v), 10 % ethanol (v/v), and 88 % water for injection (v/v) and injected together with $[^{18}\text{F}]\text{RoSMA-18-d6}$. Body temperature was monitored by a rectal probe and kept at 37°C by a heated air stream (37°C). The anesthesia depth was measured by the respiratory frequency (SA Instruments, Inc., Stony Brook, USA). μ PET acquisitions were

combined with CT for anatomical orientation and attenuation correction. The obtained data were reconstructed in user-defined time frames with a voxel size of $0.3875 \times 0.3875 \times 0.775 \text{ mm}^3$ as previously described [74].

Triphenyltetrazolium chloride (TTC) staining

To assess the ischemic lesion severity in the brain of tMCAO mice and to validate the absence of lesion in the sham-operated mice, staining with TTC staining was performed. After measurements mice were euthanized, their brains were removed and 1-mm thick brain slices were obtained with a brain matrix. Slices were incubated in a 2.5 % TTC solution (Sigma-Aldrich, Switzerland) in PBS at 37 °C for 3 min. Photographs of the brain sections were taken. Edema-corrected lesion volumes were quantified as described [75].

Biodistribution studies in the mouse brain

After PET/CT scanning of tMCAO mice at 24 h after reperfusion with [^{18}F]RoSMA-18-d6, animals were sacrificed at 70 min post injection by decapitation. The spleen and brain regions of ischemic ipsilateral area and contralateral hemisphere were collected for analysis with a gamma counter. The accumulated radioactivities in the different tissues were expressed as percent normalized injected dose per gram of tissue normalized to 20 g body weight of the animals (norm. percentage injected dose per gram tissue (% ID/g tissue)).

Data analysis and Statistics

Images were processed and analyzed using PMOD 4.2 software (PMOD Technologies Ltd., Zurich, Switzerland). The time–activity curves were deduced from specific volume-of-interest

that were defined based on a mouse MRI T₂-weighted image template [76]. Radioactivity is presented as standardized uptake value (SUV) (decay-corrected radioactivity per cm³ divided by the injected dose per gram body weight). [¹⁸F]RoSMA-18-d6 SUVR was calculated by using the midbrain in the corresponding hemisphere as reference brain region. For [¹⁸F]FDG PET, regional SUV was calculated. Two-way ANOVA with Sidak post-hoc analysis was used for comparison between groups (Graphpad Prism 9.0, CA, U.S.A).

Results

Increased expression of inflammation makers and neuronal damage after focal cerebral ischemia in tMCAO mice

mRNA levels were measured to address the question whether mouse non-ischemic and ischemic hemispheres differ in their expression levels of *CNR2* and other inflammatory genes. *CNR2* mRNA expression was increased to around 1.3 fold after 24 h reperfusion and at 48 h in the ipsilateral comparing to contralateral hemisphere (**Fig. 1a**). Similar 1.5-2.5 fold increases were observed in the mRNA expression of inflammatory markers including *TNF-α*, *Iba1*, *MMP9* and *GFAP* at 24 h and 48 h after reperfusion in the ipsilateral compared to contralateral brain region (**Fig. 1b-e**). *MAP-2* expression has been shown to be a reliable marker of neurons that undergo irreversible cell death [77, 78]. The neuron-specific *MAP-2* expression was markedly reduced in the ipsilateral compared to contralateral hemisphere at 24 h and 48 h after reperfusion (**Fig. 1f**). As similar *CNR2* mRNA expression were observed in 24 h and 48 h, our studies were performed at early time point of 24 h after reperfusion for investigating the functional, structural and molecular changes in the following experiments.

236

237 Reduced cerebral glucose metabolism and structural MRI lesion following tMCAO

238 Reduced [^{18}F]FDG uptake was observed in the presumed MCA territory of the ipsilateral

239 hemisphere in tMCAO mice, while there was no difference in [^{18}F]FDG uptake between

240 hemispheres in sham-operated mice (**Fig. 2a**). SUVs were significantly lower in the ipsilateral in

241 the striatum in tMCAO compared to the contralateral side and compared to the same region in

242 sham-operated mice 1.8 vs 1.4 (**Fig. 2b**). There were no differences in [^{18}F]FDG uptake in the

243 cortex and cerebellum between the ipsilateral and contralateral hemisphere in tMCAO mice and

244 sham-operated mice. T₂-weighted MRI and DWI imaging were performed in tMCAO and sham-

245 operated animals at 24 h after reperfusion (**Fig. 2c**). The lesions in the ipsilateral side in the

246 striatum and cortex were visible as areas of decreased values on the ADC maps calculated from

247 DWI, and as areas of increased intensities on the T₂-weighted MR images at 24 h after

248 reperfusion following 1 h tMCAO (**Figs. 2c-d**). Ischemic lesions in the tMCAO were also seen

249 *ex vivo* as white areas while viable tissue appeared red in TTC stained brain sections(**Fig. 2e**).

250 Homogenous deep red color was observed across both hemispheres in sham-operated mice,

251 verifying the absence of any lesion. The hemispheric lesion volumes in tMCAO mice were 42.8

252 ± 10.2 % (mean $\pm$ standard deviation).

253

254 Increased [^{18}F]RoSMA-18-d6 retention in the striatum after tMCAO

255 To analyze the distribution of [^{18}F]RoSMA-18-d6 in tMCAO mice brain, dynamic $\mu\text{PET/CT}$

256 scans were performed at 24 h after reperfusion. The standard uptake values (SUVs) of

257 [^{18}F]RoSMA-18-d6 did not reveal significant difference in various brain regions of tMCAO mice

258 (**Supplementary Fig 1**). However, we found a reduced uptake at early time frame (1-3 min) and

a similar uptake after 7 min in the ipsilateral side compared to that of contralateral side (Fig. 3a). Thus, to exclude the perfusion influence, we averaged the brain signals from 21-61 min and selected the midbrain as the reference region. Higher [^{18}F]RoSMA-18-d6 SUVR was observed in the ischemic ipsilateral striatum compared to the contralateral striatum (two-way ANOVA with Sidak multiple comparison correction, 0.97 ± 0.02 vs 0.87 ± 0.06 , $p = 0.0274$), but not in other brain regions such as cortex (**Fig. 3b, c**). The increased signals at ischemic ipsilateral striatum, however, could not be blocked by the selective CB₂R agonist GW405833 (**Fig. 3c**).

At the end of the *in vivo* experiments, we dissected the mice to verify the activity accumulation and specificity of [^{18}F]RoSMA-18-d6 in the spleen and different brain regions with a gamma counter. In line with the results obtained from the averaged SUVRs in the tMCAO mouse brain, the radioactivity in the ipsilateral side was indeed significant higher than that of the contralateral hemisphere (0.037 ± 0.007 vs 0.026 ± 0.003 , $n = 5$ each group), but no blockade effect was seen under blocking conditions (**Fig. 4a**). As expected, radioactivity in the CB₂R-rich spleen was much higher than the brain and 58 % of the signals was blocked by co-injection of CB₂R specific ligand GW405833, demonstrating specific target engagement of [^{18}F]RoSMA-18-d6 *in vivo* (**Fig. 4b**).

Discussion

This study assessed the utility of CB₂R PET tracer [^{18}F]RoSMA-18-d6 for imaging tMCAO mouse at subacute stage, concomitant with decreased CMRglc levels and formation of a structural lesion. Previous PET imaging of stroke animal models led to inconclusive results. In a rat model of photothrombotic stroke at 24 h after surgery, increased [^{11}C]NE40 (CB₂R tracer)

uptake and unvaried [^{11}C]PK11195 (TSPO tracer) uptake were reported [79]. In another study, [^{11}C]NE40 uptake did not show any difference in the same rat model of photothrombotic stroke [80]. Moreover, reduced [^{11}C]A836339 (CB₂R tracer) uptake was reported in a focal tMCAO rat model over 1-28 days after occlusion [51]. Possible reasons for these different observations include the time point of assessment, different methods for inducing acute stroke (transient or permanent ischemia) resulting in variations of ischemic severity and levels of inflammatory-cell expression [43].

CB₂R has negligible expression in the mouse brain and is mainly expressed in the spleen under physiological conditions [30, 36, 60-65, 81]. Under neuroinflammatory conditions, CB₂R is upregulated in activated microglial cells. In this study, we used quantitative real-time polymerase chain reaction to measure gene expression levels of *CNR2*, *TNF- α* , *Iba1*, *MMP9*, *GFAP* and *MAP-2* at 24 h and 48 h. All tested inflammatory markers displayed increased mRNA levels in the ipsilateral brain hemisphere, in agreement with the reported findings in tMCAO mouse model [29, 45, 82, 83]. In line with the increased *CNR2* gene expression levels, significantly higher [^{18}F]RoSMA-18-d6 SUVR (standard uptake value ratio) was observed in striatum at ipsilateral vs contralateral under baseline conditions in our PET studies. The 50 % reduction of the neuronal marker *MAP-2* indicated neuronal damage.

The dynamic μPET scan using [^{18}F]RoSMA-18-d6 indicated a reduced perfusion in the lesion brain regions at the first time frame of 1-3 minutes. This is probably due to the changes of microvascular response (no-reflow phenomenon) and the reduction in neuronal activity. Taking the midbrain as the reference region, the ratios of SUV averaged from 21-61 min revealed increased [^{18}F]RoSMA-18-d6 SUVR in the ipsilateral ischemic striatum compared to that of the contralateral side. Our *ex vivo* bio-distribution studies confirmed the difference of the

radioactivity distribution in the left and right brain hemisphere. The *in vivo* specificity of [¹⁸F]RoSMA-18-d6 towards CB₂R is evidenced by a 58 % reduction in radioactivity in the mouse spleen under blockade conditions in *ex vivo* biodistribution studies. Underlying reasons for the lack of specificity of [¹⁸F]RoSMA-18-d6 in the mouse brain may because 1) the increased tracer availability in the blood induced by blocking the CB₂R peripheral targets in the presence of the blocker GW405833; and 2) the relatively low brain uptake of our CB₂R-selective radioligand [¹⁸F]RoSMA-18-d6 in the mouse brain resulted in undetectable changes of radiosignals under baseline and blockade conditions. Notably, the time-activity curves of [¹⁸F]RoSMA-18-d6 in tMCAO mouse brain showed remarkably higher initial brain uptake under blockade conditions than the baseline in both sides of the mouse brain (**Supplementary Fig 1**), indicating the influence of blocking CB₂R target in the peripheral organs on the availability of radiotracer concentrations in the blood. In our previous studies with Wistar rat, the spleen uptake of [¹⁸F]RoSMA-18-d6 was blocked by nearly 90 % suggesting a high possibility of species difference of [¹⁸F]RoSMA-18-d6 binding [57]. Therefore, we speculate that rat stroke models might be superior to mice models for imaging neuroinflammation with CB₂R PET tracers.

We observed that [¹⁸F]FDG measure of CMRglc was reduced in the ischemic areas i.e. ipsilateral striatum of the tMCAO mice at 24 h after reperfusion. The reduced CMRglc was reported in many earlier studies in disease animal models and in stroke patients [84-87], masking CMRglc reduction of neuronal tissue in the brain. At an extended time points of the recovery stage from day 4 - 40, an increased CMRglc level was reported in the ischemic regions due to the increased consumption from inflammatory cells along with microglial activation [88-90].

There are several limitations in the current study. 1) As there is no reliable specific CB₂R antibody, we did not include immunohistochemical staining for CB₂R protein distribution in the

mouse brain. The qPCR measures of *CNR2* mRNA level provided an alternative readout, but do not provide spatial distribution of cerebral CB₂R expression. 2) Due to the logistic barrier, MRI and μ PET/CT scans were performed with different cohorts of animals. Nevertheless, standard operating procedures for the surgery were used. 3) Our *in vivo* data with tMCAO mice were collected at 24 h after surgery, longitudinal imaging of tMCAO mice with [¹⁸F]RoSMA-18-d6 along with structural and functional readout will provide further insight into the spatial-temporal dynamics of CB₂R expression in the brain.

Conclusion

Our newly developed CB₂R PET tracer [¹⁸F]RoSMA-18-d6 revealed limited utility to image neuroinflammation in the ischemic ipsilateral of the tMCAO mice at 24 h after reperfusion. Although lesion regions in tMCAO mouse brain could be followed by the ratios of averaged SUVs from 21-61 with midbrain as the reference region, the in-vivo specificity of [¹⁸F]RoSMA-18-d6 was confirmed only in the CB₂R-rich spleen. Different neuroinflammatory animal models which has comparable neuronal numbers in the lesion regions are recommended for evaluation of CB₂R in further PET imaging studies.

Appendix

Acknowledgements

The authors acknowledge Yingfang He, Annette Krämer at Center for Radiopharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich; Dr Mark Augath, at the Institute for Biomedical Engineering, ETH Zurich & University of Zurich for technical assistance.

351

352 **Funding**

353 JK received funding from the Swiss National Science Foundation (320030_179277), in the
354 framework of ERA-NET NEURON (32NE30_173678/1), the Synapsis Foundation, the Olga
355 Mayenfisch Stiftung, and the Vontobel foundation. RN received funding from Forschungskredit,
356 Synapsis foundation career development award (2017 CDA-03).

357

358 **Abbreviations**

359 ADC: Apparent diffusion coefficient; CB₂R: Cannabinoid type 2 receptors; CBF: Cerebral blood
360 flow; CMR_{glc}: Cerebral metabolic rate of glucose; CT: computed tomography; DW: Diffusion
361 weighted; FDG: fluorodeoxyglucose; % ID/g tissue: Injected dose per gram tissue; MRI:
362 Magnetic resonance imaging; PET: Positron emission tomography; SUV: Standardized uptake
363 value; SUVR: Standard uptake value ratio; tMCAO: transient middle cerebral artery occlusion;
364 TSPO: Translocator protein; TTC: Triphenyltetrazolium chloride.

365

366 **Availability of data and materials**

367 The data used and analyzed in the current study are available from the corresponding authors
368 upon request.

369

370 **Ethics approval and consent to participate**

All experiments were performed in accordance with the Swiss Federal Act on Animal Protection and were approved by the Cantonal Veterinary Office Zurich (permit number: ZH018/14 and ZH264/16).

Competing interests

The authors declare no conflicts of interest.

Consent for publication

Not applicable.

Authors' contribution

RN, JK, LM, SMA designed the study; RN, KC, AH, AMH, GL, LM performed the experiment, RN, LM performed data analysis, RN, JK, LM wrote the initial manuscript. All authors read and approved the final manuscript.

References

1. Kreisl WC, Kim MJ, Coughlin JM, Henter ID, Owen DR, Innis RB: **PET imaging of neuroinflammation in neurological disorders.** *Lancet Neurol* 2020, **19**:940-950.
2. Astrup J: **Energy-requiring cell functions in the ischemic brain. Their critical supply and possible inhibition in protective therapy.** *J Neurosurg* 1982, **56**:482-497.
3. Heiss W-D: **Ischemic Penumbra: Evidence From Functional Imaging in Man.** *Journal of Cerebral Blood Flow & Metabolism* 2000, **20**:1276-1293.
4. Dirnagl U, Iadecola C, Moskowitz MA: **Pathobiology of ischaemic stroke: an integrated view.** *Trends Neurosci* 1999, **22**:391-397.
5. Dabrowska S, Andrzejewska A, Lukomska B, Janowski M: **Neuroinflammation as a target for treatment of stroke using mesenchymal stem cells and extracellular vesicles.** *Journal of Neuroinflammation* 2019, **16**:178.
6. Anrather J, Iadecola C: **Inflammation and Stroke: An Overview.** *Neurotherapeutics* 2016, **13**:661-670.
7. Lambertsen KL, Finsen B, Clausen BH: **Post-stroke inflammation—target or tool for therapy?** *Acta Neuropathol* 2019, **137**:693-714.
8. Evans NR, Tarkin JM, Buscombe JR, Markus HS, Rudd JHF, Warburton EA: **PET imaging of the neurovascular interface in cerebrovascular disease.** *Nature Reviews Neurology* 2017, **13**:676-688.
9. Marchal G, Rioux P, Petit-Tabou MC, Derlon JM, Baron JC, Serrati C, Viader F, de la Sayette V, Le Doze F, Lochon P, et al: **PET imaging of cerebral perfusion and oxygen consumption in acute ischaemic stroke: relation to outcome.** *The Lancet* 1993, **341**:925-927.
10. Muir KW, Buchan A, von Kummer R, Rother J, Baron J-C: **Imaging of acute stroke.** *The Lancet Neurology* 2006, **5**:755-768.
11. Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER: **Astrocyte Biomarkers in Alzheimer's Disease.** *Trends Mol Med* 2019, **25**:77-95.
12. Jain P, Chaney AM, Carlson ML, Jackson IM, Rao A, James ML: **Neuroinflammation PET Imaging: Current Opinion and Future Directions.** *Journal of Nuclear Medicine* 2020, **61**:1107-1112.
13. Zinnhardt B, Wiesmann M, Honold L, Barca C, Schafers M, Kiliaan AJ, Jacobs AH: **In vivo imaging biomarkers of neuroinflammation in the development and assessment of stroke therapies - towards clinical translation.** *Theranostics* 2018, **8**:2603-2620.
14. Martín A, Macé E, Boisgard R, Montaldo G, Thézé B, Tanter M, Tavitian B: **Imaging of Perfusion, Angiogenesis, and Tissue Elasticity after Stroke.** *Journal of Cerebral Blood Flow & Metabolism* 2012, **32**:1496-1507.
15. Venneti S, Lopresti BJ, Wiley CA: **Molecular imaging of microglia/macrophages in the brain.** *Glia* 2013, **61**:10-23.
16. Thiel A, Heiss WD: **Imaging of microglia activation in stroke.** *Stroke* 2011, **42**:507-512.
17. Boutin H, Murray K, Pradillo J, Maroy R, Smigova A, Gerhard A, Jones PA, Trigg W: **¹⁸F-GE-180: a novel TSPO radiotracer compared to ¹¹C-R-PK11195 in a preclinical model of stroke.** *Eur J Nucl Med Mol Imag* 2015, **42**:503-511.

18. Lartey FM, Ahn GO, Shen B, Cord K-T, Smith T, Chua JY, Rosenblum S, Liu H, James ML, Chernikova S, et al: **PET Imaging of Stroke-Induced Neuroinflammation in Mice Using [18F]PBR06.** *Molecular Imaging and Biology* 2014, **16**:109-117.
19. Tóth M, Little P, Arnberg F, Häggkvist J, Mulder J, Halldin C, Gulyás B, Holmin S: **Acute neuroinflammation in a clinically relevant focal cortical ischemic stroke model in rat: longitudinal positron emission tomography and immunofluorescent tracking.** *Brain Structure and Function* 2016, **221**:1279-1290.
20. Chaney A, Cropper HC, Johnson EM, Lechtenberg KJ, Peterson TC, Stevens MY, Buckwalter MS, James ML: **¹¹C-DPA-713 versus ¹⁸F-GE-180: A preclinical comparison of TSPO-PET tracers to visualize acute and chronic neuroinflammation in a mouse model of ischemic stroke.** *Journal of Nuclear Medicine* 2018:jnumed.118.209155.
21. Martín A, Boisgard R, Thézé B, Van Camp N, Kuhnast B, Damont A, Kassiou M, Dollé F, Tavitian B: **Evaluation of the PBR/TSPO Radioligand [18F]DPA-714 in a Rat Model of Focal Cerebral Ischemia.** *Journal of Cerebral Blood Flow & Metabolism* 2009, **30**:230-241.
22. Thiel A, Radlinska BA, Paquette C, Sidel M, Soucy J-P, Schirmacher R, Minuk J: **The Temporal Dynamics of Poststroke Neuroinflammation: A Longitudinal Diffusion Tensor Imaging-Guided PET Study with ¹¹C-PK11195 in Acute Subcortical Stroke.** *Journal of Nuclear Medicine* 2010, **51**:1404-1412.
23. Zinnhardt B, Viel T, Wachsmuth L, Vrachimis A, Wagner S, Breyholz H-J, Faust A, Hermann S, Kopka K, Faber C, et al: **Multimodal Imaging Reveals Temporal and Spatial Microglia and Matrix Metalloproteinase Activity after Experimental Stroke.** *Journal of Cerebral Blood Flow & Metabolism* 2015, **35**:1711-1721.
24. Ishikawa A, Tokunaga M, Maeda J, Minamihisamatsu T, Shimojo M, Takuwa H, Ono M, Ni R, Hirano S, Kuwabara S, et al: **In Vivo Visualization of Tau Accumulation, Microglial Activation, and Brain Atrophy in a Mouse Model of Tauopathy rTg4510.** *J Alzheimers Dis* 2018, **61**:1037-1052.
25. Razansky D, Klohs J, Ni R: **Multi-scale optoacoustic molecular imaging of brain diseases.** *Eur J Nucl Med Mol Imaging* 2021.
26. Ling X, Zhang S, Shao P, Li W, Yang L, Ding Y, Xu C, Stella N, Bai M: **A novel near-infrared fluorescence imaging probe that preferentially binds to cannabinoid receptors CB2R over CB1R.** *Biomaterials* 2015, **57**:169-178.
27. Sarott RC, Westphal MV, Pfaff P, Korn C, Sykes DA, Gazzi T, Brennecke B, Atz K, Weise M, Mostinski Y, et al: **Development of High-Specificity Fluorescent Probes to Enable Cannabinoid Type 2 Receptor Studies in Living Cells.** *Journal of the American Chemical Society* 2020, **142**:16953-16964.
28. Stempel AV, Stumpf A, Zhang HY, Ozdogan T, Pannasch U, Theis AK, Otte DM, Wojtalla A, Racz I, Ponomarenko A, et al: **Cannabinoid Type 2 Receptors Mediate a Cell Type-Specific Plasticity in the Hippocampus.** *Neuron* 2016, **90**:795-809.
29. Zarruk JG, Fernandez-Lopez D, Garcia-Yebenes I, Garcia-Gutierrez MS, Vivancos J, Nombela F, Torres M, Burguete MC, Manzanares J, Lizasoain I, Moro MA: **Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternative brain macrophage/microglial activation concomitant to neuroprotection.** *Stroke* 2012, **43**:211-219.

30. López A, Aparicio N, Pazos MR, Grande MT, Barreda-Manso MA, Benito-Cuesta I, Vázquez C, Amores M, Ruiz-Pérez G, García-García E, et al: **Cannabinoid CB2 receptors in the mouse brain: relevance for Alzheimer's disease.** *Journal of Neuroinflammation* 2018, **15**:158.
31. Rodriguez-Vieitez E, Ni R, Gulyas B, Toth M, Haggkvist J, Halldin C, Voytenko L, Marutle A, Nordberg A: **Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study.** *Eur J Nucl Med Mol Imaging* 2015, **42**:1119-1132.
32. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, et al: **Neuroinflammation in Alzheimer's disease.** *Lancet Neurol* 2015, **14**:388-405.
33. Rappaport S, Backes H, Viel T, Kummer MP, Monfared P, Neumaier B, Vollmar S, Hoehn M, Van der Linden A, Heneka MT, Jacobs AH: **Imaging microglial activation and glucose consumption in a mouse model of Alzheimer's disease.** *Neurobiol Aging* 2013, **34**:351-354.
34. Yamagishi S, Iga Y, Nakamura M, Takizawa C, Fukumoto D, Kakiuchi T, Nishiyama S, Ohba H, Tsukada H, Sato K, Ouchi Y: **Upregulation of cannabinoid receptor type 2, but not TSPO, in senescence-accelerated neuroinflammation in mice: a positron emission tomography study.** *Journal of Neuroinflammation* 2019, **16**:208.
35. Di Marzo V, Stella N, Zimmer A: **Endocannabinoid signalling and the deteriorating brain.** *Nat Rev Neurosci* 2015, **16**:30-42.
36. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, et al: **Identification and functional characterization of brainstem cannabinoid CB2 receptors.** *Science* 2005, **310**:329-332.
37. Xi ZX, Peng XQ, Li X, Song R, Zhang HY, Liu QR, Yang HJ, Bi GH, Li J, Gardner EL: **Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice.** *Nat Neurosci* 2011, **14**:1160-1166.
38. Benito C, Tolón RM, Pazos MR: **Cannabinoid CB2 receptors in human brain inflammation.** *Br J Pharmacol* 2008, **153**.
39. Koppel J, Vingtdeux V, Marambaud P, D'Abramo C, Jimenez H, Stauber M, Friedman R, Davies P: **CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimer's Disease.** 2014.
40. Aso E, Ferrer I: **CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease.** *Frontiers in Neuroscience* 2016, **10**.
41. Parbo P, Ismail R, Hansen KV, Amidi A, Marup FH, Gottrup H, Braendgaard H, Eriksson BO, Eskildsen SF, Lund TE, et al: **Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease.** *Brain* 2017, **140**:2002-2011.
42. Ronca RD, Myers AM, Ganea D, Tuma RF, Walker EA, Ward SJ: **A selective cannabinoid CB2 agonist attenuates damage and improves memory retention following stroke in mice.** *Life Sci* 2015, **138**:72-77.
43. Bravo-Ferrer I, Cuartero MI, Zarruk JG, Pradillo JM, Hurtado O, Romera VG, Diaz-Alonso J, Garcia-Segura JM, Guzman M, Lizasoain I, et al: **Cannabinoid Type-2**

- 518 **Receptor Drives Neurogenesis and Improves Functional Outcome After Stroke.**
519 *Stroke* 2017, **48**:204-212.
- 520 44. Zhang M, Martin BR, Adler MW, Razdan RK, Jallo JI, Tuma RF: **Cannabinoid CB(2)**
521 **receptor activation decreases cerebral infarction in a mouse focal**
522 **ischemia/reperfusion model.** *J Cereb Blood Flow Metab* 2007, **27**:1387-1396.
- 523 45. Yu SJ, Reiner D, Shen H, Wu KJ, Liu QR, Wang Y: **Time-Dependent Protection of**
524 **CB2 Receptor Agonist in Stroke.** *PLoS One* 2015, **10**:e0132487.
- 525 46. Spinelli F, Capparelli E, Abate C, Colabufo NA, Contino M: **Perspectives of**
526 **Cannabinoid Type 2 Receptor (CB2R) Ligands in Neurodegenerative Disorders:**
527 **Structure-Affinity Relationship (SAfiR) and Structure-Activity Relationship (SAR)**
528 **Studies.** *J Med Chem* 2017.
- 529 47. Ni R, Mu L, Ametamey S: **Positron emission tomography of type 2 cannabinoid**
530 **receptors for detecting inflammation in the central nervous system.** *Acta Pharmacol*
531 *Sin* 2019, **40**:351-357.
- 532 48. Spinelli F, Mu L, Ametamey SM: **Radioligands for positron emission tomography**
533 **imaging of cannabinoid type 2 receptor.** *J Labelled Comp Radiopharm* 2018, **61**:299-
534 308.
- 535 49. Hou L, Rong J, Haider A, Ogasawara D, Varlow C, Schafroth MA, Mu L, Gan J, Xu H,
536 Fowler CJ, et al: **Positron Emission Tomography Imaging of the Endocannabinoid**
537 **System: Opportunities and Challenges in Radiotracer Development.** *Journal of*
538 *Medicinal Chemistry* 2021, **64**:123-149.
- 539 50. Varlow C, Boileau I, Wey HY, Liang SH, Vasdev N: **Classics in Neuroimaging:**
540 **Imaging the Endocannabinoid Pathway with PET.** *ACS Chem Neurosci* 2020,
541 **11**:1855-1862.
- 542 51. Pottier G, Gomez-Vallejo V, Padro D, Boisgard R, Dolle F, Llop J, Winkeler A, Martin
543 A: **PET imaging of cannabinoid type 2 receptors with [11C]A-836339 did not**
544 **evidence changes following neuroinflammation in rats.** *J Cereb Blood Flow Metab*
545 2017, **37**:1163-1178.
- 546 52. Moldovan R-P, Deuther-Conrad W, Teodoro R, Wang Y, Fischer S, Pomper M, Wong D,
547 Dannals R, Brust P, Horti A: **18F-JHU94620, a high affinity PET radioligand for**
548 **imaging of cannabinoid subtype 2 receptors (CB2R).** *Journal of Nuclear Medicine*
549 2015, **56**:1048-1048.
- 550 53. Attili B, Celen S, Ahamed M, Koole M, Haute CVD, Vanduffel W, Bormans G:
551 **Preclinical evaluation of [(18) F]MA3: a CB2 receptor agonist radiotracer for PET.**
552 *Br J Pharmacol* 2019, **176**:1481-1491.
- 553 54. Heimann D, Börgel F, de Vries H, Bachmann K, Rose VE, Frehland B, Schepmann D,
554 Heitman LH, Wünsch B: **Optimization of pharmacokinetic properties by**
555 **modification of a carbazole-based cannabinoid receptor subtype 2 (CB(2)) ligand.**
556 *Eur J Med Chem* 2018, **143**:1436-1447.
- 557 55. Kallinen A, Boyd R, Lane S, Bhalla R, Mardon K, Stimson DHR, Werry EL, Fulton R,
558 Connor M, Kassiou M: **Synthesis and in vitro evaluation of fluorine-18 benzimidazole**
559 **sulfones as CB2 PET-radioligands.** *Org Biomol Chem* 2019, **17**:5086-5098.
- 560 56. Haider A, Muller Herde A, Slavik R, Weber M, Mugnaini C, Ligresti A, Schibli R, Mu L,
561 Mensah Ametamey S: **Synthesis and Biological Evaluation of Thiophene-Based**
562 **Cannabinoid Receptor Type 2 Radiotracers for PET Imaging.** *Front Neurosci* 2016,
563 **10**:350.

57. CaillÃ F, Cacheux F, Peyronneau M-A, Jaumain E, POTTIER G, Ullmer C, Grether U, Dolle F, Damont A, Kuhnast B: **Biodistribution of [18F] FC0324, a new PET tracer targeting CB2 receptors.** *Journal of Nuclear Medicine* 2017, **58**:855-855.
58. Haider A, Gobbi L, Kretz J, Ullmer C, Brink A, Honer M, Woltering TJ, Muri D, Iding H, Bürkler M, et al: **Identification and Preclinical Development of a 2,5,6-Trisubstituted Fluorinated Pyridine Derivative as a Radioligand for the Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors.** *Journal of Medicinal Chemistry* 2020, **63**:10287-10306.
59. Haider A, Kretz J, Gobbi L, Ahmed H, Atz K, Bürkler M, Bartelmus C, Fingerle J, Guba W, Ullmer C, et al: **Structure-Activity Relationship Studies of Pyridine-Based Ligands and Identification of a Fluorinated Derivative for Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors.** *J Med Chem* 2019, **62**:11165-11181.
60. Offner H, Subramanian S, Parker SM, Afentoulis ME, Vandenbark AA, Hurn PD: **Experimental stroke induces massive, rapid activation of the peripheral immune system.** *J Cereb Blood Flow Metab* 2006, **26**:654-665.
61. Garbuzova-Davis S, Haller E, Tajiri N, Thomson A, Barretta J, Williams SN, Haim ED, Qin H, Frisina-Deyo A, Abraham JV, et al: **Blood-Spinal Cord Barrier Alterations in Subacute and Chronic Stages of a Rat Model of Focal Cerebral Ischemia.** *J Neuropathol Exp Neurol* 2016, **75**:673-688.
62. Huang B, Xie Q, Lu X, Qian T, Li S, Zhu R, Yu W, Chen G, Chen Z, Xu X, et al: **GlyT1 Inhibitor NFPS Exerts Neuroprotection via GlyR Alpha1 Subunit in the Rat Model of Transient Focal Cerebral Ischaemia and Reperfusion.** *Cell Physiol Biochem* 2016, **38**:1952-1962.
63. Dang G, Chen X, Chen Y, Zhao Y, Ouyang F, Zeng J: **Dynamic secondary degeneration in the spinal cord and ventral root after a focal cerebral infarction among hypertensive rats.** *Sci Rep* 2016, **6**:22655.
64. Moisse K, Welch I, Hill T, Volkening K, Strong MJ: **Transient middle cerebral artery occlusion induces microglial priming in the lumbar spinal cord: a novel model of neuroinflammation.** *J Neuroinflammation* 2008, **5**:29.
65. Dang G, Chen X, Zhao Y, Chen Y, Ouyang F, Liang J, Guo Y, Zeng J: **Alterations in the spinal cord and ventral root after cerebral infarction in non-human primates.** *Restor Neurol Neurosci* 2018, **36**:729-740.
66. Saleh A, Schroeter M, Jonkmanns C, Hartung HP, Mödder U, Jander S: **In vivo MRI of brain inflammation in human ischaemic stroke.** *Brain* 2004, **127**:1670-1677.
67. Ni R, Vaas M, Ren W, Klohs J: **Non-invasive detection of acute cerebral hypoxia and subsequent matrix-metalloproteinase activity in a mouse model of cerebral ischemia using multispectral-optoacoustic-tomography.** *Neurophotonics* 2018, **5**:015005.
68. Vaas M, Ni R, Rudin M, Kipar A, Klohs J: **Extracerebral Tissue Damage in the Intraluminal Filament Mouse Model of Middle Cerebral Artery Occlusion.** *Front Neurol* 2017, **8**:85.
69. Livak KJ, Schmittgen TD: **Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.** *Methods* 2001, **25**:402-408.
70. Ni R, Kindler DR, Waag R, Rouault M, Ravikumar P, Nitsch R, Rudin M, Camici GG, Liberale L, Kulic L, Klohs J: **fMRI Reveals Mitigation of Cerebrovascular**

- Dysfunction by Bradykinin Receptors 1 and 2 Inhibitor Noscipine in a Mouse Model of Cerebral Amyloidosis.** *Front aging neurosci* 2019, **11**:27-27.
71. Ni R, Rudin M, Klohs J: **Cortical hypoperfusion and reduced cerebral metabolic rate of oxygen in the arcAbeta mouse model of Alzheimer's disease.** *Photoacoustics* 2018, **10**:38-47.
72. Ren W, Skulason H, Schlegel F, Rudin M, Klohs J, Ni R: **Automated registration of magnetic resonance imaging and optoacoustic tomography data for experimental studies.** *Neurophotonics* 2019, **6**:1-10, 10.
73. Vaas M, Deistung A, Reichenbach JR, Keller A, Kipar A, Klohs J: **Vascular and Tissue Changes of Magnetic Susceptibility in the Mouse Brain After Transient Cerebral Ischemia.** *Transl Stroke Res* 2018, **9**:426-435.
74. Krämer SD, Betzel T, Mu L, Haider A, Herde AM, Boninsegni AK, Keller C, Szermerski M, Schibli R, Wünsch B, Ametamey SM: **Evaluation of (11)C-Me-NB1 as a Potential PET Radioligand for Measuring GluN2B-Containing NMDA Receptors, Drug Occupancy, and Receptor Cross Talk.** *J Nucl Med* 2018, **59**:698-703.
75. Lin TN, He YY, Wu G, Khan M, Hsu CY: **Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats.** *Stroke* 1993, **24**:117-121.
76. Ma Y, Hof PR, Grant SC, Blackband SJ, Bennett R, Slatest L, McGuigan MD, Benveniste H: **A three-dimensional digital atlas database of the adult C57BL/6J mouse brain by magnetic resonance microscopy.** *Neuroscience* 2005, **135**:1203-1215.
77. Pettigrew LC, Holtz ML, Craddock SD, Minger SL, Hall N, Geddes JW: **Microtubular proteolysis in focal cerebral ischemia.** *J Cereb Blood Flow Metab* 1996, **16**:1189-1202.
78. Dawson DA, Hallenbeck JM: **Acute focal ischemia-induced alterations in MAP2 immunostaining: description of temporal changes and utilization as a marker for volumetric assessment of acute brain injury.** *J Cereb Blood Flow Metab* 1996, **16**:170-174.
79. Hosoya T, Fukumoto D, Kakiuchi T, Nishiyama S, Yamamoto S, Ohba H, Tsukada H, Ueki T, Sato K, Ouchi Y: **In vivo TSPO and cannabinoid receptor type 2 availability early in post-stroke neuroinflammation in rats: a positron emission tomography study.** *J Neuroinflammation* 2017, **14**:69.
80. Vandeputte C, Casteels C, Struys T, Koole M, van Veghel D, Evens N, Gerits A, Dresselaers T, Lambrechts I, Himmelreich U, et al: **Small-animal PET imaging of the type 1 and type 2 cannabinoid receptors in a photothrombotic stroke model.** *Eur J Nucl Med Mol Imag* 2012, **39**:1796-1806.
81. Jordan CJ, Xi Z-X: **Progress in brain cannabinoid CB(2) receptor research: From genes to behavior.** *Neurosci Biobehav Rev* 2019, **98**:208-220.
82. Fernández-López D, Faustino J, Derugin N, Wendland M, Lizasoain I, Moro MA, Vexler ZS: **Reduced infarct size and accumulation of microglia in rats treated with WIN 55,212-2 after neonatal stroke.** *Neuroscience* 2012, **207**:307-315.
83. Zhang M, Martin BR, Adler MW, Razdan RK, Ganea D, Tuma RF: **Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury.** *Neuroscience* 2008, **152**:753-760.
84. Yuan H, Frank Jonathan E, Hong Y, An H, Eldeniz C, Nie J, Bunevicius A, Shen D, Lin W: **Spatiotemporal Uptake Characteristics of [18]F-2-Fluoro-2-Deoxy-d-Glucose in a Rat Middle Cerebral Artery Occlusion Model.** *Stroke* 2013, **44**:2292-2299.

85. Walberer M, Backes H, Rueger MA, Neumaier B, Endepols H, Hoehn M, Fink GR, Schroeter M, Graf R: **Potential of early [(18)F]-2-fluoro-2-deoxy-D-glucose positron emission tomography for identifying hypoperfusion and predicting fate of tissue in a rat embolic stroke model.** *Stroke* 2012, **43**:193-198.
86. Jin T, Mehrens H, Wang P, Kim S-G: **Chemical exchange-sensitive spin-lock MRI of glucose analog 3-O-methyl- d -glucose in normal and ischemic brain.** *Journal of Cerebral Blood Flow & Metabolism* 2017, **38**:0271678X1770741.
87. Liu N-W, Ke C-C, Zhao Y, Chen Y-A, Chan K-C, Tan D, Lee J-S, Chen Y-Y, Hsu TW, Hsieh Y-J, et al: **Evolutional Characterization of Photochemically Induced Stroke in Rats: a Multimodality Imaging and Molecular Biological Study.** *Translational Stroke Research* 2017, **8**.
88. Backes H, Walberer M, Ladwig A, Rueger MA, Neumaier B, Endepols H, Hoehn M, Fink GR, Schroeter M, Graf R: **Glucose consumption of inflammatory cells masks metabolic deficits in the brain.** *Neuroimage* 2016, **128**:54-62.
89. Sobrado M, Delgado M, Fernández-Valle E, García-García L, Torres M, Sánchez-Prieto J, Vivancos J, Manzanares R, Moro MA, Pozo MA, Lizasoain I: **Longitudinal studies of ischemic penumbra by using 18F-FDG PET and MRI techniques in permanent and transient focal cerebral ischemia in rats.** *NeuroImage* 2011, **57**:45-54.
90. Yuan H, Frank JE, Hong Y, An H, Eldeniz C, Nie J, Bunevicius A, Shen D, Lin W: **Spatiotemporal uptake characteristics of [18]F-2-fluoro-2-deoxy-D-glucose in a rat middle cerebral artery occlusion model.** *Stroke* 2013, **44**:2292-2299.

Figures

Fig 1. Relative mRNA levels of inflammatory markers and neuronal damage in sham-operated and tMCAO mouse brain in contra-and ipsilateral brain hemisphere at 24 h and 48 h after reperfusion. (a) *CNR2*, (b) *Iba1*, (c) *TNF-α*, (d) *MMP9*, (e) *GFAP* and (f) *MAP-2*. Values represent mean ± standard deviation. Expression levels were quantified by qPCR relative to β-actin.

Fig 2. *In vivo* MRI and $[^{18}\text{F}]\text{FDG}$ PET in tMCAO mouse brain. (a) Representative PET images of coronal, sagittal and horizontal mouse brain sections after intravenous injection of $[^{18}\text{F}]\text{FDG}$ in sham-operated and tMCAO mice. The radiosignals were averaged from 21-61 min; (b) $[^{18}\text{F}]\text{FDG}$ accumulation (SUV) at different mouse brain regions (Str: striatum; Ctx: cortex; Cb: cerebellum) in sham and tMCAO mice. Significantly reduced $[^{18}\text{F}]\text{FDG}$ accumulation was observed in the ipsilateral striatum compared to contralateral side in tMCAO mice; (c-e) *In vivo* T₂-weighted image, ADC map and *ex vivo* TTC stained brain sections, indicating the delineation in tMCAO mice. TTC: 2,3,5-triphenyltetrazolium chloride; ADC: apparent diffusion coefficient; SUV: standard uptake value.

Fig 3. *In vivo* microPET imaging of tMCAO mouse brain using $[^{18}\text{F}]\text{RoSMA-18-d6}$. (a) Representative PET images of horizontal mouse brain sections at different time frames after intravenous injection of $[^{18}\text{F}]\text{RoSMA-18-d6}$; SUV: 0-0.5; (b, c) Ratios of $[^{18}\text{F}]\text{RoSMA-18-d6}$ uptake under baseline and blockade conditions in cortex and striatum. Significantly higher $[^{18}\text{F}]\text{RoSMA-18-d6}$ standard uptake value ratio (SUVr) was observed in the ischemic ipsilateral striatum under baseline conditions, but not in the ipsilateral cortex. Midbrain was used as reference brain region for SUVr calculation.

Fig 4. *Ex-vivo* biodistribution of $[^{18}\text{F}]\text{RoSMA-18-d6}$ in the brain and spleen of tMCAO mouse. Animals (n=4) were sacrificed at 70 min post-injection, the spleen and brain regions were dissected and analyzed with a gamma counter. **(a)** Higher $[^{18}\text{F}]\text{RoSMA-18-d6}$ binding (norm% ID/g tissue) was detected in the ipsilateral vs contralateral hemisphere under baseline conditions. **(b)** In the spleen about 58 % of the $[^{18}\text{F}]\text{RoSMA-18-d6}$ binding (norm% ID/g tissue) was blocked. No significant blocking was observed in the brain. Data are presented as the mean of the percentage of injected dose per gram tissue normalized to 20 g body weight; mean $\pm$ standard deviation. % ID/g: percentage injected dose per gram.

719 **Additional files:**

720 Additional file 1: Supplementary Figure 1. Time activity curves of [^{18}F]RoSMA-18-d6 *in vivo*
 721 microPET imaging of tMCAO mouse brain. **(a-d)** In the cortex, striatum, cerebellum and
 722 midbrain under baseline and blockade conditions. No difference in [^{18}F]RoSMA-18-d6 SUV was
 723 observed in different brain regions at ipsilateral vs contralateral side under baseline or blockade
 724 conditions. Data represent mean $\pm$ standard deviation.

725

726 Additional file 2: Supplementary Table 1. Primers used for the quantitative polymerase chain
 727 reaction assay on mouse brain tissue

728